Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning

Unknown 202 enrolled Samsung Medical Center H. Lundbeck A/S · collab

Non-randomizedParallel-groupTriple-blindTreatment

Summary

To reveal the genetic determinants of the treatment outcome of escitalopram in depressed patients (by using candidate gene approach and whole genome scanning).

Timeline

Start: 2008-12
Primary completion: 2011-10
Completion: 2016-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Escitalopram	Small molecule	—	—

Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning

Summary

Timeline

Drugs

Indications